Form 4: Janux Therapeutics Director Jay Lichter Reports Acquisition of Shares and Stock Options

Director Jay Lichter reports acquiring shares and stock options in Janux Therapeutics, Inc.

Summary

• On June 26, 2024, Jay Lichter, a director of Janux Therapeutics, Inc., reported acquiring 2,500 shares of common stock and 8,350 stock options.
• The 2,500 shares were granted as restricted stock units (RSUs) that will vest on the earlier of June 26, 2025, or the date of the next annual meeting of the Issuer's stockholders, subject to continuous service.
• The stock options, with an exercise price of $39.80, will vest in equal monthly installments over 12 months following June 26, 2024, but will be fully vested by the date of the next annual meeting, subject to continuous service.
• Lichter also indirectly owns shares through Avalon Ventures XI, L.P. (3,271,216 shares), Avalon BioVentures I, LP (633,673 shares), and Avalon BioVentures SPV I, L.P. (3,340,018 shares), but disclaims beneficial ownership except to the extent of his pecuniary interest.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard regulatory filing detailing insider transactions. The acquisition of shares and options could be seen as a positive signal, but it's not overwhelmingly so.

Positives

• The acquisition of shares and stock options by a director signals confidence in the company's future prospects.

Future Outlook

The vesting of RSUs and stock options is contingent upon the Reporting Person's continuous service, suggesting an incentive for continued involvement with the company.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, which can be informative for investors.

Stakeholder Impact

• The transactions may influence investor perception of the company's prospects.

Key Dates